Table 4.
Phase III trials of trebananib in ovarian cancer.
| Study | Year | Setting | N | Treatment arm | PFS (median months) | PFS-HR (95% CI) | OS (median months) | OS-HR (95% CI) |
|---|---|---|---|---|---|---|---|---|
| TRINOVA-3 | 2019 | First-line treatment | 1164 | Placebo plus carboplatin and paclitaxel | 15 | 0.93 (0.79-1.09) | 43.6 | 0.99 (0.79-1.25) |
| Trebananib plus carboplatin and paclitaxel | 15.9 | 46.6 | ||||||
| TRINOVA-1 | 2014 | Recurrent ovarian cancer | 919 | Weekly paclitaxel plus placebo | 5.4 | 0.66 (0.57-0.77) | 18.3 | 0.95 (0.81-1.11) |
| Weekly paclitaxel plus trebananib | 7.2 | 19.3 | ||||||
| TRINOVA-2 | 2017 | Partially platinum sensitive or resistant | 223 | PLD plus placebo | 7.2 | 0.92 (0.68-1.24) | 17 | 0.94 (0.64-1.39) |
| PLD plus trebananib | 7.6 | 19.4 |